Neoleukin Therapeutics Stock Price

-0.12 (-3.56%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 165,571
Bid Price 2.69
Ask Price 5.69
News -
Day High 3.48


52 Week Range


Day Low 3.25
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Neoleukin Therapeutics Inc NLTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.12 -3.56% 3.25 18:00:14
Open Price Low Price High Price Close Price Prev Close
3.41 3.25 3.48 3.25 3.37
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,233 165,571 $ 3.35 $ 554,987 - 3.25 - 14.90
Last Trade Time Type Quantity Stock Price Currency
16:01:47 formt 2,186 $ 3.25 USD


Draw Mode:

Neoleukin Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 137.89M 42.43M 35.03M $ - $ - -0.65 -3.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 8.90%

more financials information »

Neoleukin Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NLTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.663.873.253.57235,287-0.41-11.2%
1 Month5.545.693.254.29210,343-2.29-41.34%
3 Months6.778.01243.255.24224,975-3.52-51.99%
6 Months8.868.903.256.30203,148-5.61-63.32%
1 Year13.6614.903.258.85200,149-10.41-76.21%
3 Years3.9818.132.5310.61287,663-0.73-18.34%
5 Years3.9818.132.5310.61287,663-0.73-18.34%

Neoleukin Therapeutics Description

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises of NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Your Recent History
Neoleukin ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.